Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Althera Medical Ltd.

This article was originally published in Start Up

Executive Summary

Alpha particle therapy is emerging as a potentially powerful weapon in the fight against cancer, but the short range of these heavy particles has limited their investigational use to date to blood cancers. Israel's Althera Medical Ltd. has found a way to deliver them into solid tumors: Its DART technology uses radioactive wires inserted in tumors to trigger a recoil mechanism that sends high-energy alpha particles throughout the mass, breaking cells' DNA and eventually eradicating the tumor.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel